47
Participants
Start Date
October 14, 2020
Primary Completion Date
March 1, 2024
Study Completion Date
March 1, 2024
MT-401
MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center, The Bronx
Mayo Clinical Cancer Center-Florida, Jacksonville
Moffitt Cancer Center, Tampa
University of Alabama at Birmingham, Birmingham
Cleveland Clinic Taussig Cancer Center, Cleveland
University of Iowa Hospitals & Clinics, Iowa City
Mayo Clinic Cancer Center-Rochester, Rochester
University of Chicago, Chicago
Baylor College of Medicine, Houston
MD Anderson Cancer Center, Houston
UCLA Department of Medicine, Los Angeles
City of Hope National Medical Center, Duarte
Moores Cancer Center at University of Californa San Diego, La Jolla
Winship Cancer Institute of Emory University, Atlanta
Yale Cancer Center, New Haven
John Theurer Cancer Center at Hackensack UMC, Hackensack
"Weill Cornell Medicine , NewYork-Presbyterian"
Lead Sponsor
Marker Therapeutics, Inc.
INDUSTRY